Eli Lilly and Company $LLY Stock: Landaas & Co. WI ADV Boosts Holdings

Landaas & Co. WI ADV increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 150.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 695 shares of the company’s stock after acquiring an additional 417 shares during the period. Landaas & Co. WI ADV’s holdings in Eli Lilly and Company were worth $804,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. TSG Advice Partners LLC bought a new stake in Eli Lilly and Company during the 3rd quarter worth about $3,970,000. Capital CS Group LLC acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth about $510,000. Independence Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company by 14.9% during the 3rd quarter. Independence Wealth Advisors LLC now owns 309 shares of the company’s stock worth $358,000 after buying an additional 40 shares during the last quarter. One Way Holdings LLC grew its holdings in shares of Eli Lilly and Company by 7.9% in the 3rd quarter. One Way Holdings LLC now owns 17,852 shares of the company’s stock valued at $20,656,000 after acquiring an additional 1,301 shares in the last quarter. Finally, Vigilare Wealth Management grew its holdings in shares of Eli Lilly and Company by 32.9% in the 3rd quarter. Vigilare Wealth Management now owns 1,819 shares of the company’s stock valued at $2,106,000 after acquiring an additional 450 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 0.2%

Shares of LLY stock opened at $1,408.68 on Wednesday. The firm has a 50 day moving average price of $1,204.03 and a two-hundred day moving average price of $1,095.92. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The company has a market capitalization of $1.33 trillion, a PE ratio of 45.72, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,449.68.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the prior year, the business earned $7.02 earnings per share. The firm’s revenue for the quarter was up 38.6% on a year-over-year basis. As a group, analysts predict that Eli Lilly and Company will post 35.61 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company’s payout ratio is 22.46%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s third-quarter revenue of $24.4 billion and EPS of $7.48 topped estimates, while revenue rose 38.6% year over year. The company raised its 2026 revenue outlook to $91 billion–$92 billion, reinforcing the demand-driven growth case. Raised Guidance Altering The Investment Case For Eli Lilly Stock?
• Positive Sentiment: Mounjaro and Zepbound remain key growth engines. Retatrutide also showed encouraging Phase 3 results versus Ozempic 2 mg in a diabetes trial, strengthening Lilly’s competitive position and future pipeline prospects. Eli Lilly Just Gained 22% in a Month
• Positive Sentiment: Cantor Fitzgerald raised its price target to $1,600 from $1,440 and maintained an “overweight” rating, reflecting optimism about the company’s outlook.
• Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale reduced her direct holdings by 54.72%, though planned insider transactions may carry less information than discretionary sales. SEC Form 4 filing
• Negative Sentiment: Some commentary warns that expectations may be ahead of sustainable growth: revenue growth could moderate, realized drug prices are reportedly falling, and some recent revenue contributions may not recur. A high valuation makes the shares more sensitive to any slowdown. Eli Lilly: Priced For Acceleration, Reporting Deceleration
• Negative Sentiment: Pipeline setbacks and dropped drug candidates outside the GLP-1 franchise raise questions about whether Lilly can broaden growth beyond its current blockbuster products. Lilly’s R&D whirlwind

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. This trade represents a 54.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 18,500 shares of company stock worth $22,970,770 in the last ninety days. 0.14% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently issued reports on LLY shares. Wells Fargo & Company upped their target price on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Friday. Royal Bank Of Canada increased their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a research report on Friday, October 30th. Citigroup raised their price target on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Morgan Stanley boosted their price target on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Finally, Leerink Partners upped their price objective on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,404.14.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.